Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex

Diagnostic Microbiology and Infectious Disease

Volumn 85, Issue 2, 2016, Pages 177-181

  Berrada, Zenda L ^a,c   Lin, Shou Yean Grace ^a   Rodwell, Timothy C ^b   Nguyen, Duylinh ^a,d   Schecter, Gisela F ^a   Pham, Lucy ^a   Janda, J Michael ^a,e   Elmaraachli, Wael ^b   Catanzaro, Antonino ^b   Desmond, Edward ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Mateo County Public Health Laboratory   (United States)

^d Roche Molecular Diagnostics   (United States)

^e Kern County Department of Public Health   (United States)

Author keywords

Molecular drug susceptibility; Multi drug resistant tuberculosis; Mycobacterium tuberculosis; Rifabutin

Indexed keywords

RIFABUTIN; RIFAMPICIN; DNA DIRECTED RNA POLYMERASE; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; VIRUS GENE; VIRUS STRAIN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MISSENSE MUTATION; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; DNA-DIRECTED RNA POLYMERASES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; RIFAMPIN; TUBERCULOSIS;

EID: 84962229368     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.01.019     Document Type: Article

References (40)

1. Anthony R.M., Schuitema A.R.J., Bergval I.L., Brown T.J., Oskam L., Klatser P.R. Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. Ann Clin Microbiol Antimicrob 2005, 4:9.
2. Aristoff P.A., Garcia G.A., Kirchhoff P.D., Showalter H.D. Rifamycins-Obstacles and opportunities. Tuberculosis 2010, 90:94-118.
3. Bernard C., Veziris N., Brossier F., Sougakoff W., Jarlier V., Robert J., et al. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015, 59(3):1519-1524. (Epub 2014 Dec 22). 10.1128/AAC.04058-14.
4. Bodmer T., Zürcher G., Imboden P., Telenti A. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995, 35:345-348.
5. Cavusoglu C., Karaca-Derici Y., Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004, 10:662-665.
6. Chen H.-Y., Yu M.-C., Huang W.-L., Wu M.-H., Chang Y.-L., Che C.-R., et al. Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis. J Clin Microbiol 2012, 50:2085-2088.
7. Clinical Laboratory Standards Institute Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard- Second Edition 2011, Clinical Laboratory Standards Institute.
8. Davies G., Cerri S., Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007, 10.1002/14651858.CD005159.pub2.
9. García A.-B., Palacios J.J., Ruiz M.-J., Barluenga J., Aznar F., Cabal M.-P., et al. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010, 54:5363-5365.
10. Gillespie S., Baskerville A., Davidson R., Felmingham D., Bryceson A. The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection. J Antimicrob Chemother 1990, 25:490.
11. Halse T.A., Edwards J., Cunningham P.L., Wolfgang W.J., Dumas N.B., Escuyer V.E., et al. Combined real-time PCR and rpoB gene pyrosequencing for rapid identification of Mycobacterium tuberculosis and determination of rifampin resistance directly in clinical specimens. J Clin Microbiol 2010, 48:1182-1188.
12. Heifets L., Lindholm-Levy P., Iseman M. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1998, 137:719.
13. Hillery N., Groessl E.J., Trollip A., Catanzaro D., Jackson L., Rodwell T.C., et al. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): Design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 2014, 15:434.
14. Horne D., Spitters C., Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis 2011, 15:1485-1490.
15. Jamieson F.B., Guthrie J.L., Neemuchwala A., Lastovetska O., Melano R.G., Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 2014, 52(6):2157-2162.
16. Krüüner A., Yates M.D., Drobniewski F.A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first-and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006, 44:811.
17. Lin S.-Y.G., Desmond E. Molecular Diagnosis of Tuberculosis and Drug Resistance. Clin Lab Med 2014, 34:297-314.
18. Lin S.-Y.G., Rodwell T.C., Victor T.C., Rider E.C., Pham L., Catanzaro A., et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 2014, 52:475-482.
19. Luna-Herrera J., Reddy M.V., Gangadharam P.R. In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J Antimicrob Chemother 1995, 36:355-363.
20. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., Gross W., Hotaling J., Kornblum J., et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999, 37:3179-3186.
21. Rigouts L., Gumusboga M., de Rijk W.B., Nduwamahoro E., Uwizeye C., de Jong B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013, 51:2641-2645.
22. Rüsch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006, 44:688.
23. Salamon H., Yamaguchi K.D., Cirillo D.M., Miotto P., Schito M., Posey J., et al. Integration of published information into a resistance-associated mutation database for Mycobaterium tuberculosis. J Inf Dis 2015, 211(S2):S50-S57.
24. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS Med 2009, 6(2).
25. Schön T., Juréen P., Chryssanthou E., Giske C.G., Sturegård E., Kahlmeter G., et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?. J Antimicrob Chemother 2013, 68:2074-2077.
26. Sintchenko V., Chew W.K., Jelfs P.J., Gilbert G.L. Mutations in RpoB Gene and Rifabutin Susceptibility of Multidrug-Resistant Mycobacterium Tuberculosis Strains Isolated in Australia. Pathology 1999, 31:257-260.
27. Sirgel F.A., Warren R.M., Böttger E.C., Klopper M., Victor T.C., van Helden P.D. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013, 8.
28. Tan Y., Hu Z., Zhao Y., Cai X., Luo C., Zou C., et al. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. J Clin Microbiol 2012, 50:81-85.
29. Uzun M., Erturan Z., Anğ O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002, 6:164-165.
30. van den Boogaard J., Kibiki G.S., Kisanga E.R., Boeree M.J., Aarnoutse R.E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009, 53:849-862.
31. Van Deun A., Barrera L., Bastian I., Fattorini L., Hoffmann H., Kam K.M., et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009, 47:3501-3506.
32. Van Deun A., Aung K.J.M., Bola V., Lebeke R., Hossain M.A., de Rijk W.B., et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013, 51:2633-2640.
33. Van Ingen J., Simons S., de Zwaan R., van der Laan T., Kamst-van Agterveld M., Boeree M.J., et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010, 48:2749-2753.
34. Van Ingen J., Aarnoutse R., de Vries G., Boeree M.J., van Soolingen D. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011, 15:990-992.
35. Williams D.L., Spring L., Collins L., Miller L.P., Heifets L.B., Gangadharam P.R., et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:1853-1857.
36. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs http://www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf.
37. World Health Organization Treatment of Tuberculosis Guidelines 2010, World Health Organization, (http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1). 4th ed.
38. Yang B., Koga H., Ohno H., Ogawa K., Fukuda M., Hirakata Y., et al. Relationship between ntimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998, 42:621-628.
39. Yoshida S., Suzuki K., Iwamoto T., Tsuyuguchi K., Tomita M., Okada M., et al. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother 2010, 16:360-363.
40. Zhao J.R., Bai Y.J., Zhang Q.H., Wang Y., Luo M., Yan X.J. Pyrosequencing-based approach for rapid detection of rifampin-resistant Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2005, 51:135-137.